readthroughSign in
CompanyTCRTNasdaqFort Lauderdale, FL

Alaunos Therapeutics, Inc.

Alaunos Therapeutics develops ALN1003, an oral small-molecule candidate for obesity and metabolic disorders.

10-QNov 16Latest SEC filing
Oct 23Latest story